Mylan Bertek Pharmaceuticals clinical trials
Acquired by Viatris Inc., Nov 16, 2020 · source ↗
The registry lists 13 studies whose lead sponsor is Mylan Bertek Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 15, 2022.
Before and after it joined Viatris Inc.
- First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- 13
- First submitted after Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Mylan Bertek Pharmaceuticals13 studies
Something wrong with this grouping? Tell us on the Viatris Inc. page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Viatris Inc. studies →
- Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With HypertensionCompletedNCT00142584Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African AmericansCompletedNCT00145210Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- Continued Efficacy of Apomorphine After Previous Exposure of at Least Three MonthsCompletedNCT00200512Phase 2/3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons DiseaseCompletedNCT00200525Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive PatientsCompletedNCT00200499Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate HypertensionCompletedNCT00200421Phase 2
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Study of the Safety and Efficacy of Nebivolol in Hypertensive PatientsCompletedNCT00200473Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive PatientsCompletedNCT00200460Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With HypertensionCompletedNCT00200434Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate HypertensionCompletedNCT00145236Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or PlaceboCompletedNCT00158093Phase 1
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.CompletedNCT00145171Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.
- Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's DiseaseCompletedNCT00142545Phase 3
Sponsor listed in the registry: Mylan Bertek Pharmaceuticals · First submitted before Mylan Bertek Pharmaceuticals became part of Viatris Inc.